AstraZeneca Signs an Agreement with Catalent to Manufacture AZD1222 for COVID-19

Shots:

• Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca at its manufacturing facility in Italy and prepare for large-scale commercial supply of AZD1222
• The agreement ramps up the production of AZD1222 and will prepare the facility to enable round-the-clock manufacturing schedules and supply hundreds of millions of doses of AZD1222 from Aug’2020 to Mar’2022
• The collaboration allows AstraZeneca to meet the global target of supplying 2B doses of its potential COVID-19 vaccine. Catalent’s 28,000 square-meter facility in Anagni offers extensive capabilities in aseptic liquid filling for biologics and sterile products across multiple vial sizes

Click here to read full press release/ article | Ref: Catalent | Image: Catalent

Related News: AstraZeneca To Supply 400M Doses of Vaccines to IVA by the End of 2020